TABLE 2.
Patient features.
| Patient features | N° | % |
| Total cases | 79 | |
| Age | ||
| Median (y) | 70 | |
| Range (y) | 39–83 | |
| ECOG PS | ||
| 0 | 31 | 40% |
| 1 | 48 | 60% |
| Gender | ||
| Male | 59 | 75% |
| Female | 20 | 25% |
| Histology | ||
| Adenocarcinoma | 51 | 65% |
| Squamous cell ca | 28 | 35% |
| Stage TNM | ||
| II | 31 | 39.2% |
| IIIA | 39 | 49.4% |
| IIIB | 9 | 11.4% |
| Adjuvant treatment | ||
| Chemotherapy | 37 | 47% |
| Radiotherapy | 20 | 25% |
| PD-L1 expression | ||
| <50% | 66 | 84% |
| ≥50% | 12 | 15% |
| PT-CD8+ expression | ||
| 0% | 7 | 9% |
| 1–33% | 14 | 18% |
| 33–66% | 34 | 43% |
| >66% | 24 | 30% |
| PT-CD4+ expression | ||
| 0% | 33 | 42% |
| 1–33% | 26 | 33% |
| 33–66% | 17 | 21% |
| >66% | 3 | 4% |
| PT-CD68+ expression | ||
| 0% | 2 | 2% |
| 1–33% | 15 | 19% |
| 33–66% | 25 | 32% |
| >66% | 37 | 47% |
| IT-CD8+ expression | ||
| 0% | 4 | 5% |
| 1–33% | 20 | 25% |
| 33–66% | 36 | 46% |
| >66% | 19 | 24% |
| IT-CD4+ expression | ||
| 0% | 25 | 32% |
| 1–33% | 34 | 43% |
| 33–66% | 17 | 21% |
| >66% | 3 | 4% |
| IT-CD68+ expression | ||
| 0% | 7 | 9% |
| 1–33% | 31 | 39% |
| 33–66% | 39 | 49% |
| >66% | 1 | 1% |
| PT/IT CD8+ ratio | ||
| <1 | 18 | 23% |
| >1 | 61 | 77% |
| PT/IT CD4+ ratio | ||
| <1 | 27 | 34% |
| >1 | 52 | 66% |
| PT/IT CD68+ ratio | ||
| <1 | 20 | 25% |
| >1 | 59 | 75% |
Ca, carcinoma; y, years; PS, performance status; IT, intratumoral; PT, peritumoral.